/GMDA
GMDA Stock - Gamida Cell Ltd.
Healthcare|BiotechnologyNASDAQ
$0.03+0.00%
+$0.00 (+0.00%) • Jun 17
63
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.50
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.79
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $0.04
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for GMDA
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$0.03 – $0.03
TARGET (TP)$0.04
STOP LOSS$0.03
RISK/REWARD1:2.7
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.03
52W High$0.04
52W Low$0.03
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $1.78M | N/A | N/A | N/A | N/A |
| Gross Profit | $-1,694,000 | $-440,000 | $-431,000 | $-357,000 | $-2,143,000 |
| Gross Margin | -95.0% | N/A | N/A | N/A | N/A |
| Operating Income | $-73,038,000 | $74.99M | $-87,167,000 | $-62,300,000 | $-48,245,000 |
| Net Income | $-62,996,000 | $-154,368,000 | $-92,419,000 | $-76,448,000 | $-34,351,000 |
| Net Margin | -3531.2% | N/A | N/A | N/A | N/A |
| EPS | $-0.42 | $-2.42 | $-1.56 | $-1.75 | $-1.17 |
Company Overview
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious hematologic diseases. The company's lead product candidate is omidubicel, a cell therapy that has completed Phase III clinical trial in patients with high-risk hematologic malignancies, as well as in Phase I/II clinical trials in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase I/II studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. In addition, the company is developing NK cell pipeline comprising GDA-301, GDA-401, GDA-501, and GDA-601 to treat hematologic malignancies and solid tumors. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
GMDABeat Rate
42%
Last 19 quarters
Avg Surprise
-3.4%
EPS vs Estimate
Beats / Misses
8/8
3 met exactly
Latest EPS
$0.13
Q2 2024
EPS Surprise History
Q3 22
0.0%
$-0.31vs$-0.31
Q4 22
+6.5%
$-0.29vs$-0.31
Q1 23
-20.8%
$-0.29vs$-0.24
Q2 23
0.0%
$-0.27vs$-0.27
Q3 23
-72.2%
$-0.31vs$-0.18
Q4 23
+93.3%
$-0.01vs$-0.15
Q1 24
+69.2%
$-0.04vs$-0.13
Q2 24
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2024 | May 20, 2024 | — | $0.13 | — | — |
Q1 2024 | Mar 27, 2024 | $-0.13 | $-0.04 | +69.2% | ✓ BEAT |
Q4 2023 | Nov 14, 2023 | $-0.15 | $-0.01 | +93.3% | ✓ BEAT |
Q3 2023 | Aug 14, 2023 | $-0.18 | $-0.31 | -72.2% | ✗ MISS |
Q2 2023 | May 15, 2023 | $-0.27 | $-0.27 | 0.0% | = MET |
Q1 2023 | Mar 27, 2023 | $-0.24 | $-0.29 | -20.8% | ✗ MISS |
Q4 2022 | Nov 14, 2022 | $-0.31 | $-0.29 | +6.5% | ✓ BEAT |
Q3 2022 | Aug 15, 2022 | $-0.31 | $-0.31 | 0.0% | = MET |
Q2 2022 | May 10, 2022 | $-0.34 | $-0.34 | 0.0% | = MET |
Q1 2022 | Mar 15, 2022 | $-0.44 | $-0.34 | +22.7% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-0.45 | $-0.33 | +26.7% | ✓ BEAT |
Q3 2021 | Aug 11, 2021 | $-0.38 | $-0.42 | -10.5% | ✗ MISS |
Q2 2021 | May 11, 2021 | $-0.39 | $-0.34 | +12.8% | ✓ BEAT |
Q1 2021 | Mar 9, 2021 | $-0.31 | $-0.68 | -119.4% | ✗ MISS |
Q4 2020 | Nov 10, 2020 | $-0.29 | $-0.30 | -3.4% | ✗ MISS |
Q3 2020 | Aug 11, 2020 | $-0.26 | $-0.37 | -42.3% | ✗ MISS |
Q2 2020 | May 21, 2020 | $-0.43 | $-0.31 | +27.9% | ✓ BEAT |
Q1 2020 | Feb 25, 2020 | $-0.39 | $-0.45 | -15.4% | ✗ MISS |
Q4 2019 | Nov 13, 2019 | $-0.37 | $-0.30 | +18.9% | ✓ BEAT |
Q3 2019 | Aug 6, 2019 | $-0.55 | $-0.87 | -58.2% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about GMDA
What is GMDA's current stock price?
Gamida Cell Ltd. (GMDA) is currently trading at $0.03 per share. The stock has moved +0.00% today.
What is the analyst price target for GMDA?
No analyst price targets are currently available for this stock.
What sector is Gamida Cell Ltd. in?
Gamida Cell Ltd. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is GMDA's market cap?
Gamida Cell Ltd. has a market capitalization of $0.00 billion, making it a small-cap company.
Does GMDA pay dividends?
No, Gamida Cell Ltd. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAPTO
Aptose Biosciences Inc.
$1.71
Mkt Cap: $0.0B
BCEL
Atreca, Inc.
$0.09
Mkt Cap: $0.0B
CYTO
Altamira Therapeutics Ltd.
$0.30
Mkt Cap: $0.0B
GRTS
Gritstone bio, Inc.
$0.03
Mkt Cap: $0.0B
HILS
Hillstream BioPharma, Inc.
$0.24
Mkt Cap: $0.0B
IDRA
Idera Pharmaceuticals, Inc.
$0.42
0NBRVF
Nabriva Therapeutics plc
$0.00
Mkt Cap: $0.0B
NEUP
Neuphoria Therapeutics Inc.
$3.89
Mkt Cap: $0.0B
RVLP
RVL Pharmaceuticals plc
$0.03
Mkt Cap: $0.0B
TNFA
TNF Pharmaceuticals, Inc.
$5.20
Mkt Cap: $0.0B
Explore stocks similar to GMDA for comparison